MEDICINE FOR IMPROVEMENT OF CEREBRAL APOPLEXY CONTAINING EUGENOL AND ITS DERIVATIVES AS EFFECTIVE INGREDIENT

摘要

Purpose: it to contain an improved medicine for eugenol and the ischemic stroke of its derived product when providing effective component, prevents or solidifies headstroke by postponing caused or from excitotoxin Acute neurotoxicity. Construction: for including an improved medicine for eugenol and its ischemic stroke as effective component derived product, it includes that NMDA (N-methyl-D-aspartate), AMPA (alpha-amido -3- hydroxy-5-methyl base -4- isoxazoles propionate) or kainate, 50% methanolic extract of the leaf from cloves show most of superior inhibition effects in the damage of nerve cell as an excitotoxin. The eugenol in the extract of the leaf of nerve cell especially relying on is protected in dosage, wherein protecting the effect to neurotoxicity, is found using NSE (neuron specific enolase) by dyeing. Eugenol derived product is same, it works as mirysticin, α-asarone (1,2,4- trimethoxies -5-prophenylbenzene), 4-allylanisole, beta-Asarone (be -2,4,5 trimethoxyprophenylbenzene) and isoeugenol when also inhibiting the neurotoxicity from excitotoxin.